Organic cation transporters in health and disease
H Koepsell - Pharmacological reviews, 2020 - ASPET
The organic cation transporters (OCTs) OCT1, OCT2, OCT3, novel OCT (OCTN) 1, OCTN2,
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …
Role of SLC transporters in toxicity induced by anticancer drugs
Introduction. Membrane transporters are integral to the maintenance of cellular integrity of all
tissue and cell types. While transporters play an established role in the systemic …
tissue and cell types. While transporters play an established role in the systemic …
Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment
S Salmaso, F Mastrotto, M Roverso, V Gandin… - Journal of Controlled …, 2021 - Elsevier
Tyrosine kinase inhibitors (TKIs) represent one of the most advanced class of therapeutics
for cancer treatment. Most of them are also cytochrome P450 (CYP) inhibitors and/or …
for cancer treatment. Most of them are also cytochrome P450 (CYP) inhibitors and/or …
Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time
D Malnoë, O Fardel, P Le Corre - Pharmaceutics, 2022 - mdpi.com
(1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic
drug–drug interactions (DDI). Identification of the nature of these DDIs, ie, enzyme-based …
drug–drug interactions (DDI). Identification of the nature of these DDIs, ie, enzyme-based …
The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
F Xiu, M Rausch, Z Gai, S Su, S Wang… - International Journal of …, 2023 - mdpi.com
Tyrosine kinase inhibitors (TKIs) decisively contributed in revolutionizing the therapeutic
approach to cancer, offering non-invasive, tolerable therapies for a better quality of life …
approach to cancer, offering non-invasive, tolerable therapies for a better quality of life …
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
J Adiwidjaja, AV Boddy, AJ McLachlan - European Journal of Clinical …, 2022 - Springer
Purpose This study implements a physiologically based pharmacokinetic (PBPK) modelling
approach to predict the effect of hydrastine and berberine, two major alkaloids present in …
approach to predict the effect of hydrastine and berberine, two major alkaloids present in …
Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors
K Alim, A Moreau, A Bruyère, E Jouan… - Fundamental & …, 2021 - Wiley Online Library
Abstract Organic cation transporter (OCT) 3 (SLC22A3) is a widely expressed drug
transporter, handling notably metformin and platinum derivatives, as well as endogenous …
transporter, handling notably metformin and platinum derivatives, as well as endogenous …
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update
In the era of precision medicine, there is increasing evidence that conventional cytotoxic
agents may be suitable candidates for therapeutic drug monitoring (TDM)-guided drug …
agents may be suitable candidates for therapeutic drug monitoring (TDM)-guided drug …
The small-molecule kinase inhibitor ceritinib, unlike imatinib, causes a significant disturbance of lipid membrane integrity: A combined experimental and MD study
M Fischer, M Luck, M Werle, A Vogel… - Chemistry and Physics …, 2023 - Elsevier
Ceritinib and imatinib are small-molecule protein kinase inhibitors which are applied as
therapeutic agents against various diseases. The fundamentals of their clinical use, ie their …
therapeutic agents against various diseases. The fundamentals of their clinical use, ie their …